{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:19:57Z","timestamp":1783005597261,"version":"3.54.5"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0080_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To determine the prevalence of erythroid dysplasia and ring sideroblasts (RS) after peripheral blood stem cell transplantation (PBSCT), stratified by transplant type, and to assess the association with\n                      <jats:italic>SF3B1<\/jats:italic>\n                      mutations and event-free survival (EFS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0080_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a retrospective single-center study, 35 adult patients undergoing PBSCT (10 haploidentical, 25 HLA-identical\/compatible) were compared to 10 controls without myeloid malignancy. Bone marrow smears collected\u00a0\u226525\u00a0days post-transplant (median 82\u00a0days) were analyzed for erythroid dysplasia (\u226510\u202f%) and RS (\u22655\u202f%) using Modified Wright and Prussian blue stains.\n                      <jats:italic>SF3B1<\/jats:italic>\n                      mutation status was assessed via NGS. EFS was calculated using Kaplan-Meier analysis; multivariate Cox regression evaluated the predictors of\u00a0EFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0080_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Erythroid dysplasia was significantly more common in PBSCT recipients than controls (p=0.011), markedly so in haploidentical recipients (8\/10, 80\u202f%) vs. HLA-identical\/compatible (8\/25, 32\u202f%) and controls (2\/10, 20\u202f%). RS\u00a0\u22655\u202f% occurred in 50\u202f% of haploidentical PBSCT, 16\u202f% of HLA-identical\/compatible PBSCT, and 0\u202f% of controls (p=0.015). However, no pathogenic\n                      <jats:italic>SF3B1<\/jats:italic>\n                      mutations were detected. In multivariate analysis, only haploidentical transplant type (HR 10.2, p=0.016) and age (HR 1.11 per year, p=0.033), but not ring sideroblastosis or erythroid dysplasia, were independent predictors of\u00a0EFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0080_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Erythroid dysplasia and RS are significantly more frequent after haploidentical PBSCT, yet in the absence of\n                      <jats:italic>SF3B1<\/jats:italic>\n                      mutations and without independent prognostic significance, they likely represent reactive marrow changes rather than clonal disease. Transplant modality and patient age remain key determinants of post-transplant outcome.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0080","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T10:20:09Z","timestamp":1777198809000},"page":"1855-1862","source":"Crossref","is-referenced-by-count":0,"title":["Post-transplant ring sideroblasts are common in haploidentical peripheral blood stem cell transplantation but not linked to\n                    <i>SF3B1<\/i>\n                    mutations"],"prefix":"10.1515","volume":"64","author":[{"given":"Marlene","family":"Hollenstein","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Allerstorfer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Flandorfer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dominik","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Internal Medicine I , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Mitterbauer","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Internal Medicine I , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Oberhauser","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00f6hrer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W.","family":"Bigenzahn","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9328-4871","authenticated-orcid":false,"given":"Klaus G.","family":"Schmetterer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Thalhammer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald F.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Unit, Department of Internal Medicine I , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-2503","authenticated-orcid":false,"given":"Helmuth","family":"Haslacher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026070213034364547_j_cclm-2026-0080_ref_001","doi-asserted-by":"crossref","unstructured":"Simpson, E, Dazzi, F. Bone marrow transplantation 1957\u20132019. Front Immunol 2019;10:1246. https:\/\/doi.org\/10.3389\/fimmu.2019.01246.","DOI":"10.3389\/fimmu.2019.01246"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_002","doi-asserted-by":"crossref","unstructured":"Meybodi, MA, Cao, W, Luznik, L, Bashey, A, Zhang, X, Romee, R, et al.. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv 2019;3:2581\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2019000614.","DOI":"10.1182\/bloodadvances.2019000614"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_003","doi-asserted-by":"crossref","unstructured":"Shah, NN, Bacher, U, Fry, T, Calvo, KR, Stetler-Stevenson, M, Arthur, DC, et al.. Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges. Am J Hematol 2012;87:916\u201322. https:\/\/doi.org\/10.1002\/ajh.23174.","DOI":"10.1002\/ajh.23174"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_004","doi-asserted-by":"crossref","unstructured":"Valent, P, Orazi, A, Steensma, DP, Ebert, BL, Haase, D, Malcovati, L, et al.. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget 2017;8:73483\u2013500. https:\/\/doi.org\/10.18632\/oncotarget.19008.","DOI":"10.18632\/oncotarget.19008"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_005","doi-asserted-by":"crossref","unstructured":"Zhang, S, Mei, Y, Zhao, B. Editorial: new insights into dyserythropoiesis: from pathophysiology, molecular mechanisms to treatments for erythroid disorders. Front Cell Dev Biol 2023;11:1321170. https:\/\/doi.org\/10.3389\/fcell.2023.1321170.","DOI":"10.3389\/fcell.2023.1321170"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_006","unstructured":"Sticco, KL, Yarrarapu, SNS, Al Obaidi, NM. Refractory anemia with ring sideroblasts. Treasure Island (FL): StatPearls; 2022."},{"key":"2026070213034364547_j_cclm-2026-0080_ref_007","unstructured":"Fujiwara, T. Ring sideroblasts and iron metabolism. Rinsho Ketsueki 2020;61:770\u20138. https:\/\/doi.org\/10.11406\/rinketsu.61.770."},{"key":"2026070213034364547_j_cclm-2026-0080_ref_008","doi-asserted-by":"crossref","unstructured":"Malcovati, L, Karimi, M, Papaemmanuil, E, Ambaglio, I, Jadersten, M, Jansson, M, et al.. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 2015;126:233\u201341. https:\/\/doi.org\/10.1182\/blood-2015-03-633537.","DOI":"10.1182\/blood-2015-03-633537"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_009","doi-asserted-by":"crossref","unstructured":"Fattizzo, B, Levati, GV, Giannotta, JA, Cassanello, G, Cro, LM, Zaninoni, A, et al.. Low-risk myelodysplastic syndrome revisited: morphological, autoimmune, and molecular features as predictors of outcome in a single center experience. Front Oncol 2022;12:795955. https:\/\/doi.org\/10.3389\/fonc.2022.795955.","DOI":"10.3389\/fonc.2022.795955"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_010","doi-asserted-by":"crossref","unstructured":"Xiong, B, Xue, M, Yu, Y, Wu, S, Zuo, X. SF3B1 mutation but not ring sideroblasts identifies a specific group of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia. Clin Lymphoma Myeloma Leuk 2020;20:329\u201339 e3. https:\/\/doi.org\/10.1016\/j.clml.2020.01.005.","DOI":"10.1016\/j.clml.2020.01.005"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_011","doi-asserted-by":"crossref","unstructured":"Jiang, M, Chen, M, Liu, Q, Jin, Z, Yang, X, Zhang, W. SF3B1 mutations in myelodysplastic syndromes: a potential therapeutic target for modulating the entire disease process. Front Oncol 2023;13:1116438. https:\/\/doi.org\/10.3389\/fonc.2023.1116438.","DOI":"10.3389\/fonc.2023.1116438"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_012","unstructured":"Macon, WRTK, Greer, JP, Wolff, SN. Ringed sideroblasts: a frequent observation after bone marrow transplantation. Mod Pathol 1995;8:782\u20135."},{"key":"2026070213034364547_j_cclm-2026-0080_ref_013","doi-asserted-by":"crossref","unstructured":"Rozman, C, Feliu, E, Gran\u1ebdna, A, Brugues, R, Woessner, S, Corrons, JLV. Transient dyserythropoiesis in repopulated human bone marrow following transplantation: an ultrastructural study. Br J Haematol 1982;50:63\u201373. https:\/\/doi.org\/10.1111\/j.1365-2141.1982.tb01891.x.","DOI":"10.1111\/j.1365-2141.1982.tb01891.x"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_014","doi-asserted-by":"crossref","unstructured":"Rozman, C, Gra\u00f1ena, A, Woessner, S. Transient ring sideroblastosis in grafted human bone-marrow. Lancet 1976;308:1364. https:\/\/doi.org\/10.1016\/s0140-6736(76)92022-5.","DOI":"10.1016\/S0140-6736(76)92022-5"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_015","doi-asserted-by":"crossref","unstructured":"Nachtkamp, K, Strupp, C, Vukelja, M, Kasprzak, A, Haase, D, Ganster, C, et al.. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the dusseldorf MDS registry and proposals for a merged classification. Leukemia 2024;38:442\u20135. https:\/\/doi.org\/10.1038\/s41375-024-02157-2.","DOI":"10.1038\/s41375-024-02157-2"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_016","doi-asserted-by":"crossref","unstructured":"Patnaik, MM, Tefferi, A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T)\u00a0\u2013\u00a0\u201c2021 update on diagnosis, risk-stratification, and management\u201d. Am J Hematol 2021;96:379\u201394. https:\/\/doi.org\/10.1002\/ajh.26090.","DOI":"10.1002\/ajh.26090"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_017","doi-asserted-by":"crossref","unstructured":"Khoury, JD, Solary, E, Abla, O, Akkari, Y, Alaggio, R, Apperley, JF, et al.. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_018","doi-asserted-by":"crossref","unstructured":"Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et al.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","DOI":"10.1038\/gim.2015.30"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_019","doi-asserted-by":"crossref","unstructured":"Yanada, M, Fukuda, T, Tanaka, M, Ota, S, Toya, T, Mori, T, et al.. Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. Bone Marrow Transplant 2020;55:2008\u201316. https:\/\/doi.org\/10.1038\/s41409-020-0868-7.","DOI":"10.1038\/s41409-020-0868-7"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_020","doi-asserted-by":"crossref","unstructured":"Sobecks, RM, Le Beau, MM, Anastasi, J, Williams, SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:1161\u20135. https:\/\/doi.org\/10.1038\/sj.bmt.1701781.","DOI":"10.1038\/sj.bmt.1701781"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_021","doi-asserted-by":"crossref","unstructured":"Patnaik, MM, Lasho, TL, Finke, CM, Hanson, CA, Hodnefield, JM, Knudson, RA, et al.. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88:201\u20136. https:\/\/doi.org\/10.1002\/ajh.23373.","DOI":"10.1182\/blood.V120.21.1711.1711"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_022","doi-asserted-by":"crossref","unstructured":"Sarchi, M, Clough, CA, Galli, A, Picone, C, Ferrari, B, Crosse, EI, et al.. Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes. Blood Adv 2025;9:3044\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2024014965.","DOI":"10.1182\/bloodadvances.2024014965"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_023","doi-asserted-by":"crossref","unstructured":"Moreno Berggren, D, Garelius, H, Willner Hjelm, P, Nilsson, L, Rasmussen, B, Weibull, CE, et al.. Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. Leukemia 2023;37:1103\u201312. https:\/\/doi.org\/10.1038\/s41375-023-01864-6.","DOI":"10.1038\/s41375-023-01864-6"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_024","doi-asserted-by":"crossref","unstructured":"Bhatia, S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013;40:666\u201375. https:\/\/doi.org\/10.1053\/j.seminoncol.2013.09.013.","DOI":"10.1053\/j.seminoncol.2013.09.013"},{"key":"2026070213034364547_j_cclm-2026-0080_ref_025","doi-asserted-by":"crossref","unstructured":"Sasaki, K, Jabbour, E, Cortes, J, Kadia, T, Garcia-Manero, G, Borthakur, G, et al.. Outcome of patients with therapy-related acute myeloid leukemia with or without a history of myelodysplasia. Clin Lymphoma Myeloma Leuk 2016;16:616\u201324. https:\/\/doi.org\/10.1016\/j.clml.2016.08.015.","DOI":"10.1016\/j.clml.2016.08.015"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0080\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:06:05Z","timestamp":1783004765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0080\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/cclm-2026-0080"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0080","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}